Abstract: As a first-in-class angiotensin receptor neprilysin inhibitor worldwide，sacubitril/valsartan has been proven to be effective and safe for heart failure and hypertension，and has also demonstrated potential therapeutic effects in acute myocardial infarction，arrhythmia and other cardiovascular diseases. As sacubitril/valsartan has been available in China recently，Chinese clinicians，especially general practitioners in primary care，have little experience in clinical use of this drug. Therefore，the General Practitioner Branch of Chinese Medical Doctor Association invited 14 experts in the field of cardiovascular medicine and general practice to develop this consensus in accordance with domestic primary care practice based on medical evidence，and relevant guidelines/consensuses. This consensus mainly focuses on the pharmacological characteristics and mechanism，medical evidence，recommendations in relevant guidelines and clinical application regarding sacubitril/valsartan. This consensus may help general practitioners in primary care to use sacubitril/valsartan reasonably and standardizedly.

Key words: Cardiovascular diseases；Receptors, angiotensin；Sacubitril/valsartan；Angiotensin receptor neprilysin inhibitor；Consensus；Primary care；General practitioners

摘要： 沙库巴曲缬沙坦钠作为全球首个血管紧张素受体脑啡肽酶抑制剂类药物，在治疗心力衰竭和高血压方面疗效确切且安全性良好，同时在急性心肌梗死及心律失常等心血管疾病中表现出潜在的治疗效果。由于沙库巴曲缬沙坦钠在我国上市时间不长，目前临床医生，特别是基层全科医生对该药的临床应用经验较少，故中国医师协会全科医师分会组织14位心血管内科、全科医学领域的专家，基于循证医学证据和国内外相关指南、共识，结合基层的临床实际制定《沙库巴曲缬沙坦钠在基层心血管疾病临床应用的专家共识》，主要包括沙库巴曲缬沙坦钠的药理学特点与作用机制、循证医学证据和相关指南推荐及临床应用方法，以期指导基层全科医生合理规范化应用沙库巴曲缬沙坦钠。

关键词: 心血管疾病；受体, 血管紧张素；沙库巴曲缬沙坦钠；血管紧张素受体脑啡肽酶抑制剂；共识；基层；全科医生